Arcus Biosciences Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −8.32%.
Did RCUS Beat Earnings? Q4 2025 Results
Arcus Biosciences delivered a stronger-than-expected Q4 2025, beating on both the top and bottom lines as investors focused increasingly on the promise of its lead oncology asset casdatifan. The clinical-stage biotech posted a loss of $0.89 per share, ahead of the $1.10 consensus estimate by 19.09%, while revenue of $33.00 million topped the $23.60 million consensus by 39.83% and rose 26.9% year over year. The outperformance was underpinned by the company's deepening late-stage pipeline investments, with R&D spend climbing to $121.00 million in the quarter as Phase 3 studies of casdatifan and quemliclustat advanced. Compelling updated data for casdatifan in clear cell renal cell carcinoma, including a 45.2% confirmed response rate and 15.1-month median progression-free survival, helped send shares sharply higher around the print. Looking ahead, management guided 2026 GAAP revenue of $45.00 million to $55.00 million and expects R&D expenses to decline meaningfully, with cash runway extending at least into the second half of 2028.
- Revenue from Gilead collaboration programs ($23 million in Q4 2025)
- Taiho option exercise for casdatifan generating $7 million in Q4 2025
- Gilead pipeline access fees of $3 million in Q4 2025
- Higher R&D expenses driven by increased enrollment in Phase 3 studies for casdatifan and quemliclustat
- Lower collaboration reimbursements as Gilead-led activities represented larger share of costs
“This week's updated data at ASCO GU continue to validate casdatifan's profile as the best-in-class HIF-2a inhibitor and new potential standard-of-care therapy for ccRCC. We are focused on rapidly enrolling PEAK-1, our Phase 3 study evaluating casdatifan plus cabozantinib in IO-experienced patients, as well as determining the optimal TKI-free casdatifan-based regimen for a registrational trial in the 1L setting by the end of the year. Together, the IO-experienced and first line settings represent an over $5 billion peak sales opportunity for casdatifan. We remain extremely well-positioned to execute on our casdatifan program and our emerging inflammation portfolio, with cash runway until at least the second half of 2028.”
Arcus Biosciences CEO, on the earnings call
Forward Guidance & Outlook
Arcus guided GAAP revenue for full-year 2026 to be between $45 million and $55 million. R&D expenses are expected to decrease meaningfully for full-year 2026 relative to 2025, with the magnitude determined in part by the results of the STAR-121 futility analysis. Cash runway is expected to extend until at least the second half of 2028. The company plans to initiate a Phase 3 study in the first-line metastatic ccRCC setting evaluating casdatifan in a TKI-free combination by the end of 2026. At least two additional data readouts for casdatifan are expected in 2026, including updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer. PRISM-1 results for quemliclustat are expected in the first half of 2027.
RCUS YoY Financials
RCUS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.